The Best and Worst Dow Stocks for the Next 12 Months

20. Amgen Inc. (NASDAQ:AMGN)

Upside Potential: 12.3%

Market Cap: $149 billion

Number of Hedge Fund Holders: 72

Amgen Inc. (NASDAQ:AMGN) is a pioneer in the biotechnology industry. It develops, manufactures, and sells innovative medicines for some of the most serious diseases, including cancer, heart disease, and osteoporosis. Close to ten of Amgen Inc.’s (NASDAQ:AMGN) products delivered at least double-digit sales growth, which helped the company’s 2024 revenue climb 19% YoY to $33.4 billion. It expects to report revenue in the $34.3-35.7 billion range in 2025.

In 2024, the company spent around $6 billion on R&D, up 25% year over year and equating to around 18.5% of total revenue. With that kind of R&D focus, the company has a strong pipeline of potentially best-in-class medicines across many therapeutic areas. The U.S. Food and Drug Administration (FDA) approved UPLIZNA as the first and only treatment for Immunoglobulin G4-related disease (IgG4-RD) in early March. This immune-mediated inflammatory condition can affect multiple organs.

In their latest updates in the last two weeks, analysts from Bernstein, Piper Sandler, and Jefferies have reiterated their Buy rating on the stock.